Finding 400807 (2022-009)

Material Weakness Repeat Finding
Requirement
I
Questioned Costs
-
Year
2022
Accepted
2024-06-13
Audit: 308831
Organization: Healthhiv (DC)
Auditor: Marcum LLP

AI Summary

  • Core Issue: HealthHIV failed to follow proper procurement processes, lacking necessary documentation and checks for vendor selection.
  • Impacted Requirements: Noncompliance with federal regulations regarding vendor selection and verification, particularly for grants ALN 93.136 and ALN 93.834.
  • Recommended Follow-Up: Implement stronger internal controls and procedures to ensure compliance with procurement regulations and prevent future issues.

Finding Text

Finding No. 2022-009: Improper Procurement Processes and Controls – Material Weakness – Internal Control and Compliance Finding ALN 93.136 – Injury Prevention and Control Research and State and Community Based Programs; Grant Number HAHSTA2020-000017; Grant Period: July 1, 2020 to August 31, 2022 ALN 93.834 – Capacity Building Assistance for High Impact HIV; Grant Number 5NU65PS923684-04-00; Grant Period: April 1, 2019 to March 31, 2024 Criteria For acquisitions exceeding the micro-purchase threshold, price or rate quotations must be obtained from an adequate number of qualified sources as determined appropriate by HealthHIV. If the procurement is sole sourced, adequate written justification for noncompetitive procurement is required. In addition, HealthHIV should verify that an entity with which it plans to enter into a covered transaction is not debarred, suspended, or otherwise excluded. This verification may be accomplished by checking the Excluded Parties List System maintained by the General Services Administration, collecting a certification from the entity, or adding a clause or condition to the covered transaction with the entity. Condition and Context HealthHIV did not have adequate internal controls in place over procurement. As a result, there was no documentation to support the rationale for selection of six vendors for ALN 93.136 and two vendors for ALN 93.834 during the year. In addition, the suspension and debarment checks for the six vendors for ALN 93.136 and two vendors for ALN 93.834 were also not performed before entering into contract with the vendors. Cause Employee turnover during the year resulted in documents being misplaced or not properly prepared. Effect HealthHIV did not fully adhere to federal laws and regulations. Questioned Costs None. Repeat Finding Yes. This was reported as Finding 2021-007. Recommendation We recommend that HealthHIV implement procedures and enhance internal controls to ensure appropriate and timely compliance with all applicable federal regulations. Views of Responsible Officials and Planned Corrective Actions See corrective action plan.

Corrective Action Plan

This action is a continued from the prior year due to the transitioning of key staff members that left the organization. We immediately implemented corrective actions to make ensure we have permanent copies of our supporting documents to solidify our vendor selections in adherence to federal regulations.

Categories

Procurement, Suspension & Debarment

Other Findings in this Audit

  • 400806 2022-008
    Material Weakness Repeat
  • 400808 2022-010
    Material Weakness Repeat
  • 400809 2022-008
    Material Weakness Repeat
  • 400810 2022-009
    Material Weakness Repeat
  • 400811 2022-010
    Material Weakness Repeat
  • 977248 2022-008
    Material Weakness Repeat
  • 977249 2022-009
    Material Weakness Repeat
  • 977250 2022-010
    Material Weakness Repeat
  • 977251 2022-008
    Material Weakness Repeat
  • 977252 2022-009
    Material Weakness Repeat
  • 977253 2022-010
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.834 Capacity Building Assistance (cba) for High-Impact Hiv Prevention $1.44M
93.136 Injury Prevention and Control Research and State and Community Based Programs $522,588
93.914 Hiv Emergency Relief Project Grants $418,119
93.118 Acquired Immunodeficiency Syndrome (aids) Activity $148,594
93.788 Opioid Str $148,315